Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6IBS

Crystal structure of NDM-1 beta-lactamase in complex with boronic inhibitor cpd 6

Summary for 6IBS
Entry DOI10.2210/pdb6ibs/pdb
DescriptorMetallo-beta-lactamase type 2, ZINC ION, [7-[(2-methylpropan-2-yl)oxycarbonylamino]-1-benzothiophen-2-yl]-tris(oxidanyl)boranuide, ... (5 entities in total)
Functional Keywordsbeta-lactamase; bacterial resistance; acyclic boronic inhibitors, hydrolase
Biological sourceKlebsiella pneumoniae
Total number of polymer chains2
Total formula weight52762.52
Authors
Maso, L.,Quotadamo, A.,Bellio, P.,Montanari, M.,Venturelli, A.,Celenza, G.,Costi, M.P.,Tondi, D.,Cendron, L. (deposition date: 2018-11-30, release date: 2019-04-24, Last modification date: 2024-01-24)
Primary citationCendron, L.,Quotadamo, A.,Maso, L.,Bellio, P.,Montanari, M.,Celenza, G.,Venturelli, A.,Costi, M.P.,Tondi, D.
X-ray Crystallography Deciphers the Activity of Broad-Spectrum Boronic Acid beta-Lactamase Inhibitors.
Acs Med.Chem.Lett., 10:650-655, 2019
Cited by
PubMed Abstract: Recent decades have witnessed a dramatic increase of multidrug resistant (MDR) bacteria, compromising the efficacy of available antibiotics, and a continual decline in the discovery of novel antibacterials. We recently reported the first library of benzo[b]thiophen-2-ylboronic acid inhibitors sharing broad spectrum activity against β-lactamases (BLs). The ability of these compounds to inhibit structurally and mechanistically different types of β-lactamases has been here structurally investigated. An extensive X-ray crystallographic analysis of boronic acids (BAs) binding to proteins representative of serine BLs (SBLs) and metallo β-lactamases (MBLs) have been conducted to depict the role played by the boronic group in driving molecular recognition, especially in the interaction with MBLs. Our derivatives are the first case of noncyclic boronic acids active against MBLs and represent a productive route toward potent broad-spectrum inhibitors.
PubMed: 30996812
DOI: 10.1021/acsmedchemlett.8b00607
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.37 Å)
Structure validation

239149

數據於2025-07-23公開中

PDB statisticsPDBj update infoContact PDBjnumon